BRIEF-MediciNova receives notice of allowance for new patent covering MN-001 and MN-002 for the treatment of fibrosis
July 26, 2016 at 01:47 AM EDT
* Says it received a notice of allowance from the U.S. Patent And Trademark Office (Uspto) for a pending patent application which covers Mn-001 (Tipelukast) and Mn-002 (A Major Metabolite Of Mn-001) for the treatment of "Fibrosis" which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes